Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
TheRas, Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located within a single distinct art unit. AULAKH, CHARANJIT is the busiest examiner for this portfolio.
Because there is only a single pending office action, the busiest examiner is responsible for the entire pending workload. The presence of a sole distinct examiner and a sole distinct art unit for this action indicates a very specific point of contact within the patent office. This ratio between pending matters and examiners suggests that the prosecution is highly concentrated.
Practitioners should focus on the specific requirements of the assigned art unit. The Biotechnology & Pharmaceuticals designation provides the technical context for this pending matter. This concentration suggests that the examiner's individual preferences will be the primary factor in the outcome of the case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291432 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291432 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | Jan 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTheRas, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Charanjit Aulakh has the most, with 1 of TheRas, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
